Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H13ClN2O |
Molecular Weight | 284.74 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(C=C(Cl)C=C2)C(=NCC1=O)C3=CC=CC=C3
InChI
InChIKey=AAOVKJBEBIDNHE-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
Molecular Formula | C16H13ClN2O |
Molecular Weight | 284.74 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24552479
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24552479
Diazepam is a benzodiazepine first discovered at Hoffman-La Roche in the late 1950s. Diazepam was approved by FDA for the treatment of anxiety disorders as well as for such conditions as skeletal muscle spasm, alcohol withdrawal syndrom and convulsions (under the most known brand Valium). The drug acts by binding to GABA-A receptors and potentiating GABA evoked current. Chronic diazepam use is associated with tolerance, dependence, and withdrawal.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24007886
Curator's Comment: # Hoffmann-La Roche
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2109243 |
8.6 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VALIUM Approved UseValium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. Launch Date-1.93449607E11 |
|||
Palliative | VALIUM Approved UseValium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. Launch Date-1.93449607E11 |
|||
Palliative | VALIUM Approved UseValium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. Launch Date-1.93449607E11 |
|||
Palliative | VALIUM Approved UseValium is indicated for the management of anxiety disorders or for the shortterm relief of the symptoms of anxiety. In acute alcohol withdrawal, Valium may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Valium is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral Valium may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. Launch Date-1.93449607E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
317 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
172 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
208 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01417078 |
20 mg single, intranasal dose: 20 mg route of administration: intranasal experiment type: single co-administered: |
DIAZEPAM plasma | Homo sapiens population: unhealthy age: sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1530 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
330 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
2 mg single, oral dose: 2 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
779 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1505149 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
DIAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1227 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01417078 |
20 mg single, intranasal dose: 20 mg route of administration: intranasal experiment type: single co-administered: |
DIAZEPAM plasma | Homo sapiens population: unhealthy age: sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
48 h |
unknown, oral |
DIAZEPAM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2% |
unknown, oral |
DIAZEPAM plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2000 mg single, oral Overdose |
healthy, 28 years |
|
500 mg single, oral Overdose |
unhealthy, 61 years |
|
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Sources: |
Other AEs: Respiratory depression, Abuse... Other AEs: Respiratory depression (serious|grade 5) Sources: Abuse (serious|grade 5) |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years n = 573 Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Population Size: 573 Sources: |
Disc. AE: Somnolence, Hypoventilation... AEs leading to discontinuation/dose reduction: Somnolence (3 patients) Sources: Hypoventilation (2 patients) Rash (2 patients) Asthenia (1 patient) Hyperkinesia (1 patient) Incoordination (1 patient) Vasodilatation (1 patient) Urticaria (1 patient) |
10 mg 2 times / day multiple, intranasal Recommended Dose: 10 mg, 2 times / day Route: intranasal Route: multiple Dose: 10 mg, 2 times / day Co-administed with:: benzodiazepines Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Respiratory depression... Other AEs: Respiratory depression (serious|grade 5) Sources: |
10 mg 4 times / day multiple, intramuscular Recommended Dose: 10 mg, 4 times / day Route: intramuscular Route: multiple Dose: 10 mg, 4 times / day Co-administed with:: benzodiazepines Sources: |
unhealthy, adult Health Status: unhealthy Condition: anxiety disorders Age Group: adult Sources: |
Other AEs: Respiratory depression, Abuse... Other AEs: Respiratory depression (serious|grade 5) Sources: Abuse (serious|grade 5) |
10 mg 4 times / day multiple, oral Recommended Dose: 10 mg, 4 times / day Route: oral Route: multiple Dose: 10 mg, 4 times / day Co-administed with:: OPIOIDS Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anxiety Disorders Age Group: adult Sources: |
Other AEs: Respiratory depression... Other AEs: Respiratory depression (serious|grade 5) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abuse | serious|grade 5 | 0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Sources: |
Respiratory depression | serious|grade 5 | 0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Sources: |
Asthenia | 1 patient Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years n = 573 Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Population Size: 573 Sources: |
Hyperkinesia | 1 patient Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years n = 573 Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Population Size: 573 Sources: |
Incoordination | 1 patient Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years n = 573 Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Population Size: 573 Sources: |
Urticaria | 1 patient Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years n = 573 Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Population Size: 573 Sources: |
Vasodilatation | 1 patient Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years n = 573 Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Population Size: 573 Sources: |
Hypoventilation | 2 patients Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years n = 573 Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Population Size: 573 Sources: |
Rash | 2 patients Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years n = 573 Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Population Size: 573 Sources: |
Somnolence | 3 patients Disc. AE |
0.2 mg/kg 2 times / day multiple, rectal Recommended Dose: 0.2 mg/kg, 2 times / day Route: rectal Route: multiple Dose: 0.2 mg/kg, 2 times / day Sources: |
unhealthy, > 12 years n = 573 Health Status: unhealthy Condition: seizure activity Age Group: > 12 years Population Size: 573 Sources: |
Respiratory depression | serious|grade 5 | 10 mg 2 times / day multiple, intranasal Recommended Dose: 10 mg, 2 times / day Route: intranasal Route: multiple Dose: 10 mg, 2 times / day Co-administed with:: benzodiazepines Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Abuse | serious|grade 5 | 10 mg 4 times / day multiple, intramuscular Recommended Dose: 10 mg, 4 times / day Route: intramuscular Route: multiple Dose: 10 mg, 4 times / day Co-administed with:: benzodiazepines Sources: |
unhealthy, adult Health Status: unhealthy Condition: anxiety disorders Age Group: adult Sources: |
Respiratory depression | serious|grade 5 | 10 mg 4 times / day multiple, intramuscular Recommended Dose: 10 mg, 4 times / day Route: intramuscular Route: multiple Dose: 10 mg, 4 times / day Co-administed with:: benzodiazepines Sources: |
unhealthy, adult Health Status: unhealthy Condition: anxiety disorders Age Group: adult Sources: |
Respiratory depression | serious|grade 5 | 10 mg 4 times / day multiple, oral Recommended Dose: 10 mg, 4 times / day Route: oral Route: multiple Dose: 10 mg, 4 times / day Co-administed with:: OPIOIDS Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anxiety Disorders Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf#page=8 Page: 8.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf#page=8 Page: 8.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf#page=8 Page: 8.0 |
no | |||
Page: 1.0 |
strong [IC50 2 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
major | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf#page=8 Page: 8.0 |
major | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020648_S002_DIASTAT_AP.pdf#page=8 Page: 8.0 |
major | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
major | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/8948091/ Page: 1.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
A comparative study of etomidate and methohexital as induction agents for analgesic anesthesia. | 1976 |
|
Reactions to intravenous injections of diazepam. | 1976 Dec |
|
Tetany, tetanus or drug reaction? A case report. | 1976 Jul |
|
[Provocation of tonic seizures during intravenous faustan administration]. | 1978 Nov |
|
Influence of adenosine agonists and antiepileptic drugs on theophylline-induced seizures in rats. | 1998 Oct |
|
Distinct features of seizures induced by cocaine and amphetamine analogs. | 1999 Jul 21 |
|
A fugue-like state associated with diazepam use. | 1999 Jun |
|
Effects of diazepam on extracellular brain neurotransmitters in pilocarpine-induced seizures in rats. | 1999 Jun 4 |
|
Transient syncope and ECG changes associated with the concurrent administration of clozapine and diazepam. | 1999 Sep |
|
Effects of anticonvulsants on local anaesthetic-induced neurotoxicity in rats. | 2000 Feb |
|
Manic episode in an ifosfamide-treated patient. | 2000 Jan-Feb |
|
Heterogeneity of GABA(A) receptor-mediated responses in the human IMR-32 neuroblastoma cell line. | 2000 May 15 |
|
Etomidate-induced convulsion prior to electroconvulsive therapy. | 2000 Oct |
|
Flumazenil prevents diazepam-elicited anticonvulsant action and concomitant attenuation of glutamate overflow. | 2000 Oct 27 |
|
Negative inotropic effect of diazepam in isolated guinea pig heart. | 2001 Feb |
|
[Prevention of postoperative nausea and vomiting in gynecologic surgery with 3 fixed doses of metoclopramide, droperidol or placebo]. | 2001 Feb |
|
Lack of reinforcing effect of the benzodiazepine and tricyclic antidepressant combination of diazepam and dothiepin. | 2001 Feb |
|
[Premedication in ambulatory surgery]. | 2001 Feb 12 |
|
Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. | 2001 Feb 2 |
|
Effects of a novel uncompetitive NMDA receptor antagonist, MRZ 2/579 on ethanol self-administration and ethanol withdrawal seizures in the rat. | 2001 Feb 9 |
|
The role of nitrergic system in lidocaine-induced convulsion in the mouse. | 2001 Jan |
|
Sedative properties of the decoction of the rhizome of Cyperus articulatus. | 2001 Jan |
|
Treatment of nonfebrile status epilepticus in Rochester, Minn, from 1965 through 1984. | 2001 Jan |
|
The effects of diazepam on sleep spindles: a qualitative and quantitative analysis. | 2001 Jan |
|
Diazepam increases the number of punished responses in a conflict-operant paradigm during late proestrus and estrus in the Wistar rat. | 2001 Jan |
|
Thiopentone induction dose requirement in dogs is little influenced by co-administration of diazepam or prior treatment with phenobarbitone or corticosteroids, but is reduced in the presence of brain pathology. | 2001 Jan |
|
Evaluating the use of benzodiazepines following recent bereavement. | 2001 Jan |
|
Brain-derived neurotrophic factor superinduction parallels anti-epileptic--neuroprotective treatment in the pilocarpine epilepsy model. | 2001 Mar |
|
Topical anesthesia for cataract surgery: a population-based perspective. | 2001 Mar |
|
Pharmacological evidence for a role of gamma-aminobutyric acid A receptor mechanism in modulating nitric oxide synthase activity in rat brain. | 2001 Mar |
|
Trimethylolpropane phosphate induces epileptiform discharges in the CA1 region of the rat hippocampus. | 2001 Mar 1 |
|
Evidence for a common binding cavity for three general anesthetics within the GABAA receptor. | 2001 Mar 15 |
|
Dual effects of melatonin on barbiturate-induced narcosis in rats. | 2001 Mar 16 |
|
The octadecaneuropeptide [diazepam-binding inhibitor (33-50)] exerts potent anorexigenic effects in rodents. | 2001 Mar 2 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 22:31:00 UTC 2023
by
admin
on
Thu Jul 06 22:31:00 UTC 2023
|
Record UNII |
Q3JTX2Q7TU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000007542
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
FDA ORPHAN DRUG |
384112
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
EPA PESTICIDE CODE |
600069
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
FDA ORPHAN DRUG |
334911
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
FDA ORPHAN DRUG |
518316
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.4
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
LIVERTOX |
NBK548352
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
WHO-VATC |
QN05BA01
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
FDA ORPHAN DRUG |
543516
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
FDA ORPHAN DRUG |
638118
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
24.3
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
FDA ORPHAN DRUG |
382512
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
WHO-ATC |
N05BA01
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
05
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
DEA NO. |
2765
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
FDA ORPHAN DRUG |
61591
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
||
|
NDF-RT |
N0000175694
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1185008
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
M4267
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | Merck Index | ||
|
169897
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
3322
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | RxNorm | ||
|
D003975
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
3057
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
Diazepam
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
DB00829
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
DTXSID4020406
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
852
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
DIAZEPAM
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
SUB07069MIG
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
3364
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
Q3JTX2Q7TU
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
C28982
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
1295
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
439-14-5
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
3016
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
CHEMBL12
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
49575
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
207-122-5
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
100000092362
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
Q3JTX2Q7TU
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
77518
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | |||
|
DIAZEPAM
Created by
admin on Thu Jul 06 22:31:02 UTC 2023 , Edited by admin on Thu Jul 06 22:31:02 UTC 2023
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Very slightly soluble in water; soluble in ethanol (~750 g/l) TS. Category: Tranquillizer. Storage: Diazepam should be kept in a well-closed container, protected from light. Definition: Diazepam contains not less than 99.0% and not more than 101.0% of C16H13ClN2O, calculated with reference to the dried substance. |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE | |||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE TOXIC -> PARENT |
Metabolite produces adverse autonomic nervous symptoms in man.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
pKa | CHEMICAL |
|
||||
Volume of Distribution | PHARMACOKINETIC |
|
||||
Tmax | PHARMACOKINETIC |
|
IV: 8 minutes |
|
||
PROTEIN BINDING | PHARMACOKINETIC |
|
||||
Biological Half-life | PHARMACOKINETIC |
|
IV: 15-21 HOURS (CHILD 2-12 YEARS) |
|||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
SEDATION, ENDOSCOPIC PROCEDURE: 20 mg IV IMMEDIATELY PRIOR TO PROCEDURE |
|
||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
BIOAVAILABILTY | PHARMACOKINETIC |
|
|
|||